DR BURKI IS AFFLIATED WITH INTERNATIONAL ORGINIZATION LIKE
(WAS) World Association Sexual Health
ISSM international society for sexual medicine
scientific and research groups of WAS
AEP Association of european psychiatrists
WPA world psychiatric association as senior member ELN
PREMATURE EJACULATION IN PAKISTAN — Lahore
• Location: Lahore, Punjab, Pakistan
• Street Address: LAHORE SPECIALIST CLINIC OPPOSIT SERVIS HOSPITAL
• Date Posted: July 14
• Phone: 03334701061
PREMATURE EJACULATION IS MOST PREVALENT SEXUAL DISORDER.IN WARM CLIMATE LIKE PAKISTAN AVERAGE SEX TIMING OF MALE IS MINIMUM.INCMOPTABILITY OF TIMING BETWEEN MALE AND FEMALE HAS CAUSED FRUSTRATION IN COUPLE.COMPLIAN OF DROPS (DHANT) AND EXCESSIVE NOCTURAL EMISSION(AHTHALAM) ARE ASSOCIATED DISORDERS.MANY PATIENT S GET HOOKED TO ADDICTION DUE TO THIS ORDER.
DR MUHAMMAD HARIS BURKI IS WORLD WIDE AUTHORITY DEALING WITH THIS PROBLEM.HE HAS CONDUCTED RESEARCHES PRESENTED PAPERS ON THIS TOPIC ,IN ALL PARTS OF WORLD.HE IS DESIGNER OF NEW TECNIQUE FOR DELAYING EJAVULATION COMMONLY KNOWN AS BURKI,S MANOUVER.HE ALSO HAS INTRODUCED NEW MEDICATION GABAPENTINE FOR TREATMENT OF PREMATURE EJACULATION IN MADRID (SPAIN) IN CONGRESS OF EUROPEAN PSYCHIATRY.DR BURKIHAS DISCOVERED INTIMATE RELATION BETWEEN AXIETY DEPRESSION AND PREMATURE EJACULATION.HE HAS EXCLUSIVE TREATMENT FOR CONCOMITANT PSYCHIATRIC PAIN AND MISERY.
VERY RECENTLY DR BURKI HAS DESIGNED NEW MANOEUVRE BURKI II FOR PREMATURE EJACULATION.C;Just click following links
MUHAMMAD HARIS BURKI
MBBS, PHD (sexology) WPA -CME (psych)USA
ELECTED MEMBER WORLD ASSOCIATION OF SEXUAL HEALTH
MEBER PSYCHIATRY AND SEXUAL HEALTH COMMITTEE WORLD SPSYCHIATRIC ASSOCIATION
MEMBER EUROPEAN PSYCHIARTIC
PDE5 Inhibitors for LUTS: Discussion
Authors and Disclosures
Print This Email this
Abstract and Introduction
AH and the Metabolic Syndrome
The Effects of PDE5 Inhibitors on LUTS
MEDSCAPE’S FREE MOBILE APP
Experience the fastest, most comprehensive, FREE medical app used by physicians.
Available for iPhone®, iPod touch®, iPad™, Android™, and BlackBerry®
Learn more Discussion
Both ED and LUTS secondary to BPH are found to be increasingly prevalent as men age. Several large epidemiologic studies have shown an association between LUTS and ED independent of age and other co-morbidities, implying a causal relationship. Few studies have examined a temporal association, and further research is required.[91,92] Four possible pathophysiologic mechanisms have been described and may explain the role of PDE5-inhibitor therapy in LUTS. PDE5 inhibitors facilitate smooth muscle relaxation through the NO/cGMP pathway, with effects in the bladder, prostate, and urethra. This theory is supported by the findings of multiple large trials showing significant improvement in LUTS after PDE5-inhibitors therapy. In addition, PDE5 inhibitors have been shown to counter AH (which is mediated through increased second messengers NE and endothelin levels). Rho-kinase’s effects are mediated in part by these same second messengers, and it too can be affected by PDE5 inhibitors. Pelvic atherosclerosis and ischemia tie together all these concepts. In its presence, Rho-kinase is upregulated, NOS is downregulated, and AH is induced as a component of the metabolic syndrome.
The results of these studies imply that PDE5 inhibitors predominantly improve storage symptoms (IPSS) rather than voiding symptoms (Qmax). However, the exact mechanism of action is not well understood. Earlier studies have shown increased LUTS in aging men and women, pointing to a source other than the prostate causing these symptoms. Experimental models, in human and rat tissue, have shown that PDE5 inhibitors decrease nonvoiding bladder contractions.[94,83] In addition, PDE5 inhibitors have been shown to improve urodynamic parameters in SCI patients. PDE5 inhibitors offer an opportunity to treat ED and LUTS concurrently. Furthermore, there may be a role of PDE5 inhibitors in the treatment of LUTS in men without ED and in women.
« Previous Page Section 9 of 9 Table of Contents
Abstract and Introduction Background Epidemiologic Data NOS/NO Theory AH and the Metabolic Syndrome Rho-kinase Activation Pelvic Atherosclerosis The Effects of PDE5 Inhibitors on LUTS Discussion
[ CLOSE WINDOW ]
1.Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006; 49: 651–659.
2.Untergasser G, Madersbacher S, Berger P. Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol 2005; 40: 121–128.
3.McVary KT. BPH: epidemiology and comorbidities. Am J Manag Care 2006; 12: S122–S128.
4.Guess HA, Arrighi HM, Metter EJ, Fozard JL. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate 1990; 17: 241–246.
5.Chute CG, Panser LA, Girman CJ, Oesterling JE, Guess HA, Jacobsen SJ et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993; 150: 85–89.
6.Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54–61.
7.Girman CJ, Jacobsen SJ, Tsukamoto T, Richard F, Garraway WM, Sagnier PP et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998; 51: 428–436.
8.Guest JF, Das Gupta R. Health-related quality of life in a UK-health-related quality of life in a UK-based population of men with erectile dysfunction. Pharmacoeconomics 2002; 20: 109–117.
9.Calais Da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrick DL. Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study. Eur Urol 1997; 31: 272–280.
10.Kirby RS. The natural history of benign prostatic hyper-plasia: what have we learned in the last decade? Urology 2000; 56: 3–6.
11.Lukacs B, Leplège A, Thibault P, Jardin A. Prospective study of men with clinical benign prostatic hyperplasia treated with alfuzosin by general practitioners: 1-year results. Urology 1996; 48: 731–740.
12.Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I, Rodriguez-Vela L, Jimenez-Cruz JF, Burgos-Rodriguez R. Prevalence and independent risk factors for erectile dysfunction in Spain: results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol 2001; 166: 569–575.
13.Braun MH, Sommer F, Haupt G, Mathers MJ, Reifenrath B, Engelmann UH. Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical ‘aging male’ symptoms? Results of the ‘Cologne Male Survey’. Eur Urol 2003; 44: 588–594.
14.Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637–649.
15.Andersson KE. Erectile physiological and pathophysiological pathways involved in erectile dysfunction. J Urol 2003; 170: S6–14.
16.Carvajal JA, Germain AM, Huidobro-Toro JP, Weiner CP. Molecular mechanism of cGMP-mediated smooth muscle relaxation. J Cell Physiol 2000; 184: 409–420.
17.Kohler TS, McVary KT. The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors. Eur Urol 2009; 55: 38–48.
18.Andersson KE, Persson K. Nitric oxide synthase and the lower urinary tract: possible implications for physiology and pathophysiology. Scand J Urol Nephrol 1995; 175 (Suppl): 43–53.
19.Hedlund P. Nitric oxide/cGMP-mediated eVects in the out-Xow region of the lower urinary tract—is there a basis for pharmacological targeting of cGMP? World J Urol 2005; 23: 362–367.
20.Andersson KE. LUTS treatment: future treatment options. Neurourol Urodyn 2007; 26: 928–933.
21.Burnett AL, Maguire MP, Chamness SL, Ricker DD, Takeda M, Lepor H et al. Characterization and localization of nitric oxide synthase in the human prostate. Urology 1995; 45: 435–439.
22.Richter K, Heuer O, ckert S, Stief CG, Jonas U, Wolf G. Immunocytochemical distribution of nitric oxide synthases in the human prostate. J Urol 2004; 171 (Suppl 4): 347 (abstract).
23.Bloch W, Klotz T, Loch C, Schmidt G, Engelmann U, Addicks K. Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate 1997; 33: 1–8.
24.Gradini R, Realacci M, Ginepri A, Naso G, Santangelo C, Cela O et al. Nitric oxide synthases in normal and benign hyperplastic human prostate: immunohistochemistry and molecular biology. J Pathol 1999; 189: 224–229.
25.Luo J, Dunn T, Ewing C, Sauvageot J, Chen Y, Trent J et al. Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis. Prostate 2002; 51: 189–200.
26.Uckert S, Oelke M, Stief CG, Andersson KE, Jonas U, Hedlund P. Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 2006; 49: 740–745.
27.Morley DJ, Hawley DM, Ulbright TM, Butler LG, Culp JS, Hodes ME. Distribution of phosphodiesterase in normal human tissues. J Histochem Cytochem 1987; 35: 75–82.
28.Truss MC, Stief CG, Uckert S, Becker AJ, Wefer J, Schultheiss D et al. Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to bedside. World J Urol 2001; 19: 344–350.
29.Longhurst PA, Briscoe JA, Rosenberg DJ, Leggett RE. The role of cyclic nucleotides in guinea-pig bladder contractility. Br J Pharmacol 1997; 121: 1665–1672.
30.Snyder PB, Loughney K, Florio VA. Relaxation of bladder strips by inhibition of cyclic nucleotide phosphodiesterase type 4 (PDE4) (abstract 159). J Urol 2005; 173: 43.
31.Gillespie JI. Phosphodiesterase-linked inhibition of nonmicturition activity in the isolated bladder. BJU Int 2004; 93: 1325–1332.
32.Werkstrom V, Svensson A, Andersson K-E, Hedlund P. Phosphodiesterase 5 in the female pig and human urethra: morphological and functional aspects. BJU Int 2006; 98: 414–423.
33.Oger S, Behr-Roussel D, Lecoz O, Lebret T, Denoux Y, Bernabé J et al. Evaluation of relaxant effects of the combination of sildenafil and doxazosin in human prostate. Eur Urol Suppl 2007; 6: 33.
34.McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007; 177: 1401–1407.
35.Takeda M, Tang R, Shapiro E, Burnett AL, Lepor H. Effects of nitric oxide on human and canine prostates. Urology 1995; 45: 440–446.
36.Kedia G, ckert S, Scheller F, Chigogidze T, Managadze L, Jonas U et al. In vitro functional responses of isolated normal human prostatic tissue to compounds interacting with the cyclic guanosine monophosphate pathway. Urology 2006; 67: 1292–1297.
37.Kedia G, ckert S, Kedia M, Truss MC, Chigogidze T, Jonas U et al. In vitro effects of drugs interfering with the cAMP- and cGMP-pathway on the tension induced by endothelin-1 of isolated human prostate tissue. Georgian Med News 2006; 131: 7–13.
38.Guh JH, Hwang TL, Ko FN, Chueh SC, Lai MK, Teng CM. Antiproliferative effect in human prostatic smooth muscle cells by nitric oxide donor. Mol Pharmacol 1998; 53: 467–474.
39.Ückert S, Sormes M, Kedia G, Gratzke C, Stief CG, Scheller F et al. Effects of PDE inhibitors on the tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostate tissue. Urology 2006; 45 (Suppl 1): 25–26 (abstract).
40.Kedia G, Sormes M, ckert S, Scheller F, Jonas U. Contraction-relaxation studies on isolated human prostate tissue: the role of endothelin 1, phosphodiesterase inhibitors and cyclic nucleotides. Eur Urol 2007; 6 (Suppl 2): 34 (abstract).
41.Snyder PB, Loughney K, Florio VA. Relaxation of bladder strips by inhibition of cyclic nucleotide phosphodiesterase type 4 (PDE4) (abstract 159). J Urol 2005; 173: 43.
42.Gillespie JI, Markerink-van Ittersum M, de Vente J. cGMP-generating cells in the bladder wall: identification of distinct networks of interstitial cells. BJU Int 2004; 94: 1114–1124.
43.Gillespie JI, Markerink-van Ittersum M, de Vente J. Expression of neuronal nitric oxide synthase (nNOS) and nitric-oxide-induced changes in cGMP in the urothelial layer of the guinea pig bladder. Cell Tissue Res 2005; 321: 341–351.
44.Gillespie JI, Markerink-van Ittersum M, De Vente J. Endogenous nitric oxide/cGMP signalling in the guinea pig bladder: evidence for distinct populations of sub-urothelial interstitial cells. Cell Tissue Res 2006; 325: 325–332, 1489–1495.
45.Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415–1428.
46.Hammarsten J, Hogstedt B, Holthuis N, Mellstrom D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998; 1: 157–162.
47.Hammarsten J, Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 1999; 8: 29–36.
48.Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001; 54: 935–944.
49.McVary KT, Razzaq A, Lee C, Venegas MF, Rademaker A, McKenna KE. Growth of the rat prostate gland is facilitated by the autonomic nervous system. Biol Reprod 1994; 51: 99–107.
50.Golomb E, Rosenzweig N, Eilam R, Abramovici A. Spontaneous hyperplasia of the ventral lobe of the prostate in aging genetically hypertensive rats. J Androl 2000; 21: 58–64.
51.Rahman NU, Phonsombat S, Bochinski D, Carrion RE, Nunes L, Lue TF. An animal model to study lower urinary tract symptoms and erectile dysfunction: the hyperlipidemic rat. BJU Int 2007; 100: 658–663.
52.Persson K, Pandita RK, Spitsbergen JM, Steers WD, Tuttle JB, Andersson KE. Spinal and peripheral mechanisms contributing to hyperactive voiding in spontaneously hypertensive rats. Am J Physiol 1998; 275: 1366–1373.
53.Hale TM, Okabe H, Bushfield TL, Heaton JP, Adams MA. Recovery of erectile function after brief aggressive anti-hypertensive therapy. J Urol 2002; 168: 348–354.
54.McVary KT, Rademaker A, Lloyd GL, Gann P. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2005; 174: 1327–1433.
55.Holmquist F, Andersson KE, Hedlund H. Actions of endothelin on isolated corpus cavernosum from rabbit and man. Acta Physiol Scand 1990; 139: 113–122.
56.Azadzoi KM, Kim N, Brown ML, Goldstein I, Cohen RA, Saenz de Tejada I. Endothelium-derived nitric oxide and cyclooxygenase products modulate corpus cavernosum smooth muscle tone. J Urol 1992; 147: 220–225.
57.Uckert S, Sormes M, Kedia G, Scheller F, Knapp WH, Jonas U et al. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue. Urology 2008; 71: 526–530.
58.Ahn GJ, Yu JY, Choi SM, Kang KK, Ahn BO, Kwon JW et al. Chronic administration of phosphodiesterase 5 inhibitor improves erectile and endothelial function in a rat model of diabetes. Int J Androl 2005; 28: 260–266.
59.Rees RW, Ziessen T, Ralph DJ, Kell P, Moncada S, Cellek S. Human and rabbit cavernosal smooth muscle cells express Rho-kinase. Int J Impot Res 2002; 14: 1–7.
60.Somlyo AP, Somlyo AV. Signal transduction by G-proteins, Rho-kinase and protein phosphatase to smooth muscle and non smooth muscle myosin II. J Physiol 2000; 522: 177–185.
61.Rees RW, Foxwell NA, Ralph DJ, Kell PD, Moncada S, Cellek S. Y-27632, a Rho-kinase inhibitor, inhibits proliferation and adrenergic contraction of prostatic smooth muscle cells. J Urol 2003; 170: 2517–2522.
62.Lindberg C, Nishtman D, Malmqvist UP, Abrahamsson PA, Andersson KE, Hedlund P et al. Increased expression of RhoA in prostates of spontaneously hypertensive rats. J Urol 2004; 171 (Suppl): 348, A1320.
63.Bing W, Chang S, Hypolite JA, DiSanto ME, Zderic SA, Rolf L et al. Obstruction-induced changes in urinary bladder smooth muscle contractility: a role for Rho kinase. Am J Physiol Renal Physiol 2003; 285: F990–F997.
64.Chang S, Hypolite JA, Zderic SA, Wein AJ, Chacko S, DiSanto ME. Increased corpus cavernosum smooth muscle tone associated with partial bladder outlet obstruction is mediated via Rho-kinase. Am J Physiol Regul Integr Comp Physiol 2005; 289: R1124–R1130.
65.Chang S, Hypolite JA, Changolkar A, Wein AJ, Chacko S, DiSanto ME. Increased contractility of diabetic rabbit corpora smooth muscle in response to endothelin is mediated via Rho-kinase beta. Int J Impot Res 2003; 15: 53–62.
66.Seko T, Ito M, Kureishi Y, Okamoto R, Moriki N, Onishi K et al. Activation of RhoA and inhibition of myosin phosphatase as important components in hypertension in vascular smooth muscle. Circ Res 2003; 92: 411–418.
67.Rajasekaran M, White S, Baquir A, Wilkes N. Rho-kinase inhibition improves erectile function in aging male Brown-Norway rats. J Androl 2005; 26: 182–188.
68.Tarcan T, Azadzoi KM, Siroky MB, Goldstein I, Krane RJ. Age related erectile and voiding dysfunction: the role of arterial insufficiency. Brit J Urol 1998; 82: 26–33.
69.Ponholzer A, Temml C, Wehrberger C, Marszalek M, Maderbacher S. The association between LUTS and vascular risk factors in both sexes. Eur Urol 2006; 50: 581–586.
70.Azadzoi KM, Tarcan T, Siroky MB, Krane RJ. Atherosclerosis-induced chronic ischemia causes bladder fibrosis and noncompliance in the rabbit. J Urol 1999; 161: 1626–1635.
71.Kozlowski R, Kershen RT, Siroky MB, Krane RJ, Azadzoi KM. Chronic ischemia alters prostate structure and reactivity in rabbits. J Urol 2001; 165: 1019–1026.
72.Azadzoi KM, Babayan RK, Kozlowski R, Siroky MB. Chronic ischemia increases prostatic smooth muscle contraction in the rabbit. J Urol 2003; 170: 659–663.
73.McVary K. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005; 47: 838–845.
74.Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. BJU Int 2002; 90: 836–839.
75.Mulhall JP, Guhring P, Parker M, Hopps C. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006; 3: 662–667.
76.Ying J, Yao D, Jiang Y, Ren X, Xu M. The positive effect of sildenafil on LUTS from BPH while treating ED. Zhonghua Nan Ke Xue 2004; 10: 681–683.
77.Kaplan SA, Gonzalez RR, Te AE. Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 2007; 51: 1717–1723.
78.McVary KT, Monnig W, Camps JL, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function andprostatic hyperplasia, low- and high-grade prostatic intraepithelial neoplasia and prostatic carcinoma. BJU Int 2007; 88: 100–103.
79.Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomized, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008; 53: 1236–1244.
80.Roehrborn CG, McVary KT, Elion-Mboussa A, Viktrup L. Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008; 180: 1228–1234.
81.Roehrborn RC. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo controlled trial. Urology 2001; 58: 953–959.
82.Gacci M, Del Populo G, Macchiarella A, Celso M, Vittori G, Lapini A et al. Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 2007; 178: 2040–2043.
83.Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M et al. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007; 148: 1019–1029.
84.Yono M, Yamamoto Y, Yoshida M, Ueda S, Latifpour J. Effects of doxazosin on blood Xow and mRNA expression of nitric oxide synthase in the spontaneously hypertensive rat genitourinary tract. Life Sci 2007; 81: 218–222.
85.Pinggera GM, Schuster A, Frauscher F, Bartsch G, Strasser H. Sildenafil citrate causes a 3-fold increase in periurethral prostatic blood Xow. J Urol 2004; 171 (Suppl 4): 355 (abstract).
86.Guh JH, Hwang TL, Ko FN, Chueh SC, Lai MK, Teng CM. Antiproliferative effect in human prostatic smooth muscle cells by nitric oxide donor. Mol Pharmacol 1998; 53: 467–547.
87.Adolfsson PI, Ahlstrand C, Varenhorst E, Svensson SP. Lysophosphatidic acid stimulates proliferation of cultured muscle cells from human BPH tissue: sildenafil and papaverine generate inhibition. Prostate 2002; 51: 50–58.
88.Deng CH, Chen HR, Qiu SP, Liu JZ, Zheng KL, Mei H. Effect of nitric oxide donor and alpha1-receptor antagonist on proliferation/apoptosis of hyperplastic prostatic stromal cells in vitro. Zhonghua Wai Ke Za Zhi 2004; 42: 201–204.
89.Uckert S, Kuthe A, Jonas U, Stief CG. Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 2001; 166: 2484.
90.Dmochowski R, Roehrborn C, Kraus S, Klise S. Changes in bladder outlet obstruction index in men with signs and symptoms of benign prostatic hyperplasia treated with tadalafil. J Urol 2009; (suppl): 181: (abstract 1924).
91.Moreira Jr ED, Lbo CF, Diament A, Nicolosi A, Glasser DB. Incidence of erectile dysfunction in men 40 to 69 years old: results from a population-based cohort study in Brazil. Urology 2003; 61: 431–436.
92.Shiri R, Hakkinen JT, Hakama M, Huhtala H, Auvinen A, Tammela TL et al. Effect of lower urinary tract symptoms on the incidence of erectile dysfunction. J Urol 2005; 174: 205–209.
93.Chai TC, Belville WD, McGuire EJ, Nyquist L. Specificity of the American Urological Association Voiding Symptom Index: comparison of unselected and selected samples of both sexes. J Urol 1993; 150: 1710–1713.
94.Tinel H, Stelte-Ludwig B, Hütter J, Sandner P. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 2006; 98: 1259–1263